CAHC supports the revised pilot as a targeted approach to preventing duplicate discounts and improving transparency in the 340B program.
- It changes only the mechanism and timing of the discount so that claims can be validated before payment, helping prevent overlapping 340B and Medicare negotiated-price discounts.
- The pilot is limited to drugs selected for IRA price controls for 2026 and 2027 (less than 5.5 percent of total 340B sales) and includes safeguards intended to protect covered-entity cash flow.
- Importantly, the pilot does not change the amount of the 340B discount, patient eligibility, or which entities qualify for the program.
We encourage Congress to continue to evaluate the program, and reform areas where the vaguely and poorly drafted statute fails to deliver lower costs for patients and taxpayers.
Download Resource